InsiderTrades.com logo
Wall Street Legend Warns "Mass Bank Run" is Coming
From Chaikin Analytics   |   Ad
Man who predicted 2023 bank run warns it could soon get worse. Get out of cash and into a new vehicle 50 years in the making. Click here to learn more.
Click here to learn more.

1AD Insider Trading

Insider Ownership Percentage: 32.86%
Insider Buying (Last 12 Months): A$0.00
Insider Selling (Last 12 Months): A$0.00

AdAlta Insider Trading History Chart

This chart shows the insider buying and selling history at AdAlta by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

AdAlta Share Price & Price History

Current Price: A$0.00
Price Change: +0.30 (1.20%)
As of 05/13/2020 01:00 AM ET

This chart shows the closing price history over time for 1AD up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Free Stock Analysis Report: Buy Sell Hold Predictions on Any Stock
From Vector Vest   |   Ad
Get a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation.
Analyze Any Stock Free

AdAlta Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/29/2023David FullerInsiderTransfer210,668A$0.02A$5,056.03
1/23/2023Elizabeth (Liddy) McCallInsiderTransfer54,059,848A$0.04A$2,054,274.22
2/7/2022Robert PeachInsiderIssued116,661A$0.07A$8,516.25
11/26/2021Timothy OldhamInsiderBuy61,000A$0.12A$7,320.00
10/26/2021Timothy OldhamInsiderBuy235,000A$0.09A$19,975.00
11/26/2020Timothy OldhamInsiderBuy61,000A$0.12A$7,320.00
See Full Table
Wall Street Legend Warns "Mass Bank Run" is Coming
From Chaikin Analytics   |   Ad
Man who predicted 2023 bank run warns it could soon get worse. Get out of cash and into a new vehicle 50 years in the making. Click here to learn more.
Click here to learn more.

SEC Filings (Institutional Ownership Changes) for AdAlta (ASX:1AD)

19.90% of AdAlta stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

AdAlta logo
AdAlta Limited, a clinical stage biotechnology company, discovers and develops protein therapeutics by its i-body platform in Australia. Its lead product is AD-214, an antibody therapeutic, which is in Phase I clinical trial for the treatment of fibrotic diseases, including idiopathic pulmonary fibrosis and interstitial lung disease, kidney fibrosis, eye fibrosis, and various cancers. AdAlta Limited has collaborative partnerships with GE Healthcare to develop i-body enabled granzyme B PET imaging agents for use in immuno-oncology; and Carina Biotech to develop CAR-T cell products against various solid tumor antigens. The company was incorporated in 2006 and is based in Bundoora, Australia.
Read More on AdAlta

Today's Range

Now: N/A

50 Day Range

MA: N/A

52 Week Range

Now: N/A

Volume

135,957 shs

Average Volume

N/A

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.71

Who are the company insiders with the largest holdings of AdAlta?

AdAlta's top insider investors include:
  1. David Fuller (Insider)
  2. Elizabeth (Liddy) McCall (Insider)
  3. Robert Peach (Insider)
  4. Timothy Oldham (Insider)
Learn More about top insider investors at AdAlta.
Transform Your Portfolio With This Simple Morning Trade!
From Base Camp Trading   |   Ad
Hi, I’m trading expert Dave Aquino and I want to show you how to take advantage of a trading opportunity happening nearly every morning at 9:30 EST.

My free guide, “How To Master The Retirement Trade” will show you exactly why traders in the know want to keep this trade a secret.
Claim your copy now!